Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma

Baykara M., Akkus M., Yildiz R., GÖNÜL İ. I. , DURSUN A., Coskun U., ...Daha Fazla

INTERNATIONAL IMMUNOPHARMACOLOGY, cilt.11, sa.12, ss.2227-2231, 2011 (SCI İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Konu: 12
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.intimp.2011.10.005
  • Sayfa Sayıları: ss.2227-2231


This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in gastrointestinal stromal sarcoma (GIST). Twenty patients (12 males and 8 females) ranging in age from 25 to 72, with a median age of 53 were evaluated. Failure of TKI treatment was higher in the survivin-positive group (p= 0.06). The rate of metastasis was significantly higher in the survivin positive group vs. the negative group (80% vs. 30%, p =0.18). The median overall survival (OS) time was 114 (range 29-199) months, and the median disease-free survival (DFS) time was 88 (range 40-135) months. The median progression-free survival (PFS) time was 40 (range 24-55) months. Further, a comparison of patients with survivin positive versus negative tumors, revealed no significant difference for OS, DFS, and PFS (p = 0.45, p = 0.19, p= 0.55, respectively), number of mitoses in 50 HPF (p =0.14), and tumor size (p = 0.94).